0248 Efficacy of a novel intranasal Zn solution on health and growth performance of high risk, newly received stocker cattle

Abstract The study objective was to determine the effects of Bacillus subtilis PB6 and/or chromium propionate supplementation on health, growth performance, and carcass characteristics of high-risk beef cattle during a 56-d feedlot receiving period and the subsequent finishing period. Four truckload blocks of crossbred beef bulls (n = 300) and steers [n = 84; body weight (BW) = 220 ± 16.2 kg] were sourced from regional auction markets and assigned randomly to treatments arranged in a 2 × 2 factorial. The generalized complete block design consisted of 12 pen replications per treatment with pen as the experimental unit. Treatments were: 1) placebo control (CON); 2) 13 g per animal daily of B. subtilis PB6 (CST); 3) 450 ppb dry matter (DM) chromium propionate (CHR); and 4) 13 g per animal daily of B. subtilis PB6 and 450 ppb DM chromium propionate (CST + CHR). Treatments were top dressed in feed bunks daily using 0.45 kg per animal ground corn carrier immediately following feed delivery. Data were analyzed using mixed models. During the receiving period, dry matter intake (DMI) increased (P ≤ 0.03) for CST during each interim period. Overall receiving period daily DMI was 0.35 kg per animal greater for CST (P = 0.01). Cattle fed CST had greater (P ≤ 0.06) BW on days 14, 28, and 56. Likewise, average daily gain (ADG) was improved for CST from day 0 to 14 (P = 0.04) and for the overall receiving period (days 0–56; P = 0.04). From days 0 to 14, CST tended (P = 0.08) to increase gain:feed. During the finishing period, CHR reduced (P = 0.02) final BW and ADG (day 56 to final; P = 0.01) and ADG was less for CHR over the entire feeding period (day 0 to final; P = 0.03). The main effect of both CST (P = 0.02) and CHR (P = 0.03) decreased the overall treatment rate for bovine respiratory disease (BRD), and CST reduced overall antimicrobial treatment cost by $3.50 per animal compared to CON (P = 0.03). Hot carcass weight (HCW) decreased (P = 0.01) in cattle fed CHR. The percentage of edible livers tended to increase (CST × CHR; P = 0.08) in the CST treatment. Feed intake and growth performance outcomes during the receiving period were improved by CST but not CHR supplementation. However, both CST and CHR supplementation decreased the BRD morbidity rate. During the finishing period, performance and HCW were reduced in cattle supplemented with CHR.

Download Full-text

PSVI-2 The effect of a recombinant Mannheimia haemolytica leukotoxoid on the health and growth performance of high-risk, newly received stocker cattle metaphylactically treated with tilmicosin

Journal of Animal Science ◽

10.1093/jas/skz258.405 ◽

2019 ◽

Vol 97 (Supplement_3) ◽

pp. 196-197

Author(s):

Autumn T Pickett ◽

Jase Ball ◽

Elizabeth Kegley ◽

Ken Blue ◽

Jacob A Hagenmaier ◽

...

Keyword(s):

Body Weight ◽

High Risk ◽

Antibody Response ◽

Growth Performance ◽

Respiratory Disease ◽

Bovine Respiratory Disease ◽

Average Daily Gain ◽

Mannheimia Haemolytica ◽

Type I ◽

Bovine Virus Diarrhea

Abstract Crossbred male beef calves (n = 259; bulls = 134, steers = 125; body weight = 250 ± 3.4 kg) approximately 6 months of age and considered high-risk for developing bovine respiratory disease arrived on 3 dates (block) and were stratified by arrival castrate status and weight to be evenly distributed across pens (8 pens/block; 9 to 12 calves/pen). The pens were randomly assigned to 1 of 2 treatments: 1) Nuplura PH (administration of a Mannheimia haemolytica leukotoxoid at processing) or 2) Control (no M. haemolytica leukotoxoid). All cattle received tilmicosin on d 0 with a 5-d post-metaphylactic interval. Body weights were recorded on d -1, 0, 14, 28, 41 and 42. Blood was collected on d -1, 14, 28, and 42 and sera were harvested to determine serum neutralization titers for bovine virus diarrhea (BVD) type I and bovine anti-M. haemolytica leukotoxin antibodies. Calves were observed daily for signs of morbidity. Body weight and average daily gain were not affected (P ≥ 0.26) by treatment. The percentage of calves administered 1, 2, or 3 antibiotic treatments for clinical bovine respiratory disease did not differ (P ≥ 0.35). There was a tendency for mortality to be greater for Control compared to Nuplura PH (1.6 vs 0.0%; P = 0.10). Calves administered Nuplura PH possessed greater antibody response against M. haemolytica leukotoxin on d 14, 28, and 42 compared to Control calves (P < 0.01). There was no treatment × day interaction for antibody titers against BVD (P = 0.98). The use of a M. haemolytica leukotoxoid had no effect on growth performance and morbidity for the 42-d following receiving in this small-pen study, but reduced the incidence of mortality and did not interfere with antibody response to BVD vaccination in high-risk, newly received calves metaphylactically treated with tilmicosin on arrival.

Download Full-text

PSXIV-35 Evaluation of a direct fed microbial in newly received, high-risk beef calves and the subsequent impact on performance and health

Journal of Animal Science ◽

10.1093/jas/skz258.857 ◽

2019 ◽

Vol 97 (Supplement_3) ◽

pp. 432-433

Author(s):

Ellen Herring ◽

Jase Ball ◽

Elizabeth Kegley ◽

James Turner ◽

Elizabeth Palmer ◽

...

Keyword(s):

Body Weight ◽

High Risk ◽

Growth Performance ◽

Propionibacterium Freudenreichii ◽

Study Objective ◽

Beef Calves ◽

The Mean ◽

Antibiotic Cost ◽

Lactobacillus Animalis

Abstract Crossbred beef calves [n = 240, body weight (BW) = 257 ± 3.5 kg] were obtained on 3 dates (block, 8 pens/block) and were assigned randomly to 1 of 2 treatments: 1) CON = top-dress supplement (0.11 kg/d) with no direct-fed microbial, 2) BOV = top dress supplement (0.11 kg/d) that provided 113.5 mg/d of a direct-fed microbial (BOVAMINE DEFEND®, 2 g/d, Lactobacillus animalis, Propionibacterium freudenreichii, 1 × 109 CFU2/g). Study objective was to determine the effect of BOV on growth performance and health when included in the diet. From d 0 to 14, ADG was improved (P = 0.05) for BOV compared to CON as ADG were 0.89 and 0.74 kg, respectively. Overall ADG over the 43-d receiving period was not different (P = 0.65); numerically there was a 0.03 kg improvement in BOV (0.90) compared to CON (0.87 kg). The percentage of calves treated for clinical BRD with the first treatment antibiotic (florfenicol) was not affected (P = 0.40); however, was numerically reduced by 6.8% for BOV (61.2% morbidity) compared to CON (68.0% morbidity). There was a trend for the percentage of calves treated with a second antibiotic (enrofloxacin) to be reduced (P = 0.17) for calves supplemented with BOV (9.1%) compared to CON (15.2%). There was also a trend for the mean total number of antibiotics used to be reduced (P = 0.16) in BOV compared to CON. Overall antibiotic cost, was not affected (P = 0.23) by BOV supplementation; however, numerically there was a $3.27 reduction in antibiotic cost for BOV compared to CON. The supplementation of BOV in high-risk calves may improve growth performance and health, reduce clinical BRD in calves after first treatment and could potentially reduce the use of antibiotics in calves at a high risk for BRD during the receiving period.

Download Full-text